Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020088703 - A METHOD OF PREDICTING A RISK OF CARDIOVASCULAR DISEASE FOR A CHILD BORN FROM A COMPLICATED PREGNANCY

Publication Number WO/2020/088703
Publication Date 07.05.2020
International Application No. PCT/CZ2019/050050
International Filing Date 30.10.2019
IPC
C12Q 1/6883 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
CPC
C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
C12N 2310/141
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
10Type of nucleic acid
14interfering N.A.
141MicroRNAs, miRNAs
C12N 2320/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2320Applications; Uses
10in screening processes
C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
C12Q 2600/118
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
118Prognosis of disease development
Applicants
  • UNIVERZITA KARLOVA, 3.LEKARSKA FAKULTA [CZ]/[CZ]
Inventors
  • HROMADNIKOVA, Ilona
Agents
  • HARTVICHOVA, Katerina
Priority Data
PV 2018-59531.10.2018CZ
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) A METHOD OF PREDICTING A RISK OF CARDIOVASCULAR DISEASE FOR A CHILD BORN FROM A COMPLICATED PREGNANCY
(FR) PROCÉDÉ DE PRÉDICTION D'UN RISQUE DE MALADIE CARDIOVASCULAIRE CHEZ UN ENFANT NÉ D'UNE GROSSESSE AVEC COMPLICATIONS
Abstract
(EN)
The present invention provides a method of predicting a risk of onset and development of cardiovascular disease for a child born from a pregnancy complicated by gestational hypertension, preeclampsia and/or fetal growth restriction, or in a child born from a physiological pregnancy having an abnormal postnatal clinical finding, said method comprising the steps of: - determining the level of expression of at least one microRNA marker selected from the group consisting of miR-1-3p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-21-5p, miR-23a-3p, miR-26a-5p, miR-29a-3p, miR-103a-3p, miR-125b-5p, miR-126-3p, miR-133a-3p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-210-3p, miR-342-3p and combinations thereof, in a sample of blood taken from the child; - comparing the determined level(s) of expression of the said at least one microRNA marker with reference cut-off value, wherein said reference cut-off value is obtained by statistical analysis of samples from children from physiological pregnancies and samples from children from complicated pregnancies; - wherein the aberrant regulation of the said at least one microRNA marker exceeding the reference cut-off value, or below the reference cut-off value, respectively, indicates the risk of onset and development of cardiovascular disease for the child.
(FR)
La présente invention porte sur un procédé de prédiction d'un risque d'apparition et de développement d'une maladie cardiovasculaire chez un enfant né d'une grossesse compliquée par l'hypertension gestationnelle, la prééclampsie et/ou la restriction de croissance foetale, ou chez un enfant porté à partir d'une grossesse physiologique ayant une découverte clinique postnatale anormale, ledit procédé comprenant les étapes suivantes : -établissement du niveau d'expression d'au moins un marqueur de microARN choisi dans le groupe constitué par miR-1-3p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-21-5p, miR-23a-3p, miR-26a-5p, miR-29a-3p, miR-103a-3p, miR-125b-5p, miR-126-3p, miR-133a-3p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-210-3p, miR-342-3p et de leurs combinaisons, dans un échantillon de sang prélevé sur l'enfant;-comparaision du/des niveau(x) déterminé(s) de l'expression dudit au moins un marqueur de microARN avec une valeur limite de référence, ladite valeur limite de référence étant obtenue par analyse statistique d'échantillons provenant d'enfants à partir de grossesse physiologiques et d'échantillons provenant d'enfants à partir de grossesse avec complications; -la régulation aberrante dudit au moins un marqueur de microARN dépassant la valeur limite de référence, ou se situant au-dessous de la valeur limite de référence, respectivement, indique le risque d'apparition et de développement d'une maladie cardiovasculaire pour l'enfant.
Latest bibliographic data on file with the International Bureau